APR 2 8 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant(s): Ralph A. REISFELD, et al.

Serial No. 10/090,183 Attorney Docket No.: (TSRI-829.0)

Filed: March 2, 2002) Group Art: 1645

For: DNA VACCINE AGAINST)
PROLIFERATING ENDOTHELIAL CELLS)
AND METHODS OF USE THEREOF

Examiner: Not Yet Assigned) TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D. C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56, §1.97 and §1.98, documents that may be material to the examination of this application are listed on the attached PTO-1449 form. Copies of each document are enclosed.

The cited documents disclose numerous specific features. There has been no attempt to enumerate each and every feature disclosed by each document, however. The Examiner is requested to review these documents and to determine the extent of the materiality of the document disclosures, if any, with respect to the present invention.

The discussion of any art and the citation of any document herein is not to be construed as an admission that the art or document disclosure is necessarily within the invention field of endeavor, that the art or document disclosure is necessarily prior in time to a particular date which may be relevant to the instant patent application, and/or that the art or document disclosure is otherwise necessarily prior art as defined by the patent law with respect to the instant invention and application.

Serial No.

10/090,183

Filed:

March 2, 2002

Also, there is reserved the right to later set forth how the claimed invention is distinguished over the disclosure of any document or other art, including the disclosures of the art and documents recited herein, and that may be cited by the Examiner in rejecting a claim in the instant patent application.

-2-

The recitation herein of the art and documents is not to be construed as an assertion that more pertinent art could not possibly be in existence.

Respectfully submitted,

a livalde (obutil

OLSON & HIERL, LTD. 20 North Wacker Drive 36th Floor Chicago, Illinois 60606 (312) 580-1180 Serial No. 10/090,183 Filed: March 2, 2002

-3-

CERTIFICATE OF MAILING

I hereby certify that this correspondence and attachments are being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 2021, on 27 Hours 2023.

Talivaldis Cepuritis



PTO/SB/08A (02-03)

Approved for use through 04/30/2003 OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

rmation unless if contains a valid OHS co Complete if Known Application Number 10/090,183 Filing Date March 2, 2002 First Named Inventor Raiph A. REISFELD 9 Art Unit 1645 Examiner Name Attomey Docket Number TSRI-829.0

U. S. PATENT DOCUMENTS					
Examiner in Lais*	No.	Document Number Number-Kind Code ^{2 (A known)}	Publication Date MM-DD-YYYY	Name of Palentee or Applicant of Cited Document	Pages, Columns, Light Where Relevant Passages of Relevant Figures Appear
		^{US-} 5,851,999	12/22/1998	Ullrich, et al.	
		US 5,939,400	8/17/1999	Steinman, et al.	
		US- 6,086,891	7/11/2000	Hurwitz, et al.	
		US- 6,214,804 B1	4/10/2001	Felgner, et al.	
		US- 6,228,844 B1	5/8/2001	Wolff, et al.	
		US 6,235,523 B1	5/22/2001	Gajewczyk, et al.	
		US-			
	-	US-			
		US-			
		US			
		US-			
-	•	u.S.			
_		US			+
		US-			
	-	U\$-			
	-	us.			
		US-			
	-	US-			
	i	US-			

Examiner Initials*	C te	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T.c
		Country Code' Number Kind Code of known	MM-DD-YYYY			
		WO 02/03961 A1	1/17/2002	Corixa Corp.		

Signature Considered

EXAMABLE into I reference considered whether or not obtain is in conformance with VPEP 600 Draw the brough clast or find in conformance and not considered include copy of this form with most combination to pape and. Applicants unless likely coephage for more profession. See Kins Blooks of USEP 0 Parel Documents at www. upda.gog or MPEP 800 LG. Their Office that is assuch the document, by the two laters once (VPP Distances 13 Lg. Frances and the common services of the parel of the finance must precise the same number of the patient occurrent. Kind of occurrently the appropriate symbols as indicated on the document in Just 10 decisions. Application of the patient occurrent. Kind of occurrently appropriate professions as indicated on the document injuries. Translation is attached

This collection of information is required by 37 CFR 197 and 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentially is governed by 50 US C 122 and 50 CFR. 1.4 Time will vary depending upon the individual case. Any comments for the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chef Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

PTO/SB/08B (02-03)

Approved for use through 04/30/2003 OMB 0551-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE and to a collection of information unless a contains a vaid OMB control number.

Complete if Known.

Substitute for form 1449/PTO	Joinpiete ii ii	
	Application Number	10/090,183
INFORMATION DISCLOSURE	Filing Date	March 2,2002
STATEMENT BY APPLICANT	First Named Inventor	Ralph A. REISFELD
	Antilant	

(Use as many sheets as necessary)

2

Sheet

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
nitials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
		Shin SASAKI, et al., NATURE BIOTECHNOLOGY, Vol. 19, pp. 543-547 (June 2001).	
		Nicholas P RESTIFO, NATURE BIOTECHNOLOGY, Vol. 19, pp. 527-528 (June 2001).	
	į.	Wolfgange W. LEITNER, et al., CANCER RESEARCH, Vol. 60, pp. 51-55 (January 1, 2000).	
	į	N P RESTIFO et al. GENE THERAPY Vol. 7 pp. 89-92 (2000)	
		Bruce A. KEYT. et al., THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 271, No. 10, pp. 5638-5646 (1996).	
		Yu-Quan WEI, et al., NATURE MEDICINE, Vol. 6, No. 10, pp. 1160-1166 (October 2000)	
		William MATTHEWS, et al., PROC. NAT'L. ACAD. SCI., USA, Vol. 88, pp 9026-9030 (October 1991)	
		Timothy P QUINN, et al., PROC NAT'L, ACAD SCI , USA Vol 90, pp 7533-7537 (Aug. 1993).	
		Rong XIANG, et al., CLINICAL CANCER RESEARCH, Vol. 7, pp. 856s-864s (March 2001) (Suppl.)	
		Andreas G NIETHAMMER et al. NATURE MEDICINE. Vol. 8 (12) pp. 1369-1375 (December, 2002)	

Examiner	Date	
Signature	Considered	

*EXAMINER: Install freference considered, whether or not otation is in conformance with MPEP 609. Drawline through citation from in conformance and not considered. Include copy of this form with next communication to applicant.

unsidense, Include copy of the form with rest communication to applicant. Appeared is not provided to the provided p

If you need assistance in completing the form call 1-800 PTO 9199 (1-800-786-9199) and select option 2